Shots:

• KU Leuven to receive an up front & is eligible to receive additional development, regulatory, and commercialization milestones along with royalties on net sales of products that emerges from the collaboration
• Under the collaboration, Biohaven gets exclusive global rights to develop, manufacture, and commercialize KU Leuven's BHV-2100 (TRPM3 antagonists) which is expected to enter in clinical development in H1’23 for neuropathic pain
• Biohaven will be responsible to support basic and translational research of TRPM3 in pain and other disorders. Additionally, BHV-2100 showed promising efficacy in preclinical pain models and will move towards P-I studies

Ref: PR Newswire | Image: PR Newswire